EyePoint Pharmaceuticals, Inc. Common Stock (EYPT) Stock
Key stats
- Market cap
- $30.74M
- Price / Earnings ratio
- -0.1x
- EPS (TTM)
- -$3.75
- Volume
- Loading
- 52-week high
- $19.11
- 52-week low
- $0.33
Source: third-party data provider, as of November 13, 2026
Compare with EYPT
Recent news

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EYPT

Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today?
Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today?
EYPT

Here's Why You Should Add EYPT Stock to Your Portfolio Now
Here's Why You Should Add EYPT Stock to Your Portfolio Now
EYPT

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
EYPT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 18.82
- MACD 12/26/9
- -0.72
- EMA 9 of MACD
- -0.86
- MACD histogram
- 0.14
- SMA 50
- $2.50
- Price below SMA 50
- EMA 50
- $2.80
- Price below EMA 50
- SMA 200
- $10.37
- Price below SMA 200
- EMA 200
- $9.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EYPT

Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today?
Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today?
EYPT

Here's Why You Should Add EYPT Stock to Your Portfolio Now
Here's Why You Should Add EYPT Stock to Your Portfolio Now
EYPT

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
EYPT

EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
EYPT

EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
EYPT

NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
EYPT

EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
EYPT

EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EYPT

Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
EYPT
News tone: automated (AI) classification of the article's content, not a price prediction.
About EyePoint Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jay S. Duker M.D. | President, CEO & Director | 1959 |
| Mr. George O. Elston CPA | Executive VP & CFO | 1965 |
| Dr. Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer | 1983 |
| Dr. Marcia Sellos-Moura Ph.D. | Chief Scientific Officer | — |
| Mr. Ron I. Honig Esq. | Chief Legal Officer & Company Secretary | — |
| Ms. Jennifer Leonard | Chief People Officer & Senior VP of IT | — |
| Mr. David Scott Jones M.A. | Senior Vice President | 1968 |
| Ms. Isabelle Lefebvre | Chief Regulatory Officer | — |
| Mr. Michael J. Maciocio | Chief Manufacturing Officer | — |
| Mr. Michael Campbell | Chief Commercial Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 18.82
- MACD 12/26/9
- -0.72
- EMA 9 of MACD
- -0.86
- MACD histogram
- 0.14
- SMA 50
- $2.50
- Price below SMA 50
- EMA 50
- $2.80
- Price below EMA 50
- SMA 200
- $10.37
- Price below SMA 200
- EMA 200
- $9.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $1.00
- Average
- $7.00
- High
- $17.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +10.5 | -21.1 | ||||||||||
| 2022 | -23.7 | +0.7 | +24.0 | -7.0 | -19.7 | -12.2 | +17.8 | +9.8 | -19.9 | -24.3 | -41.0 | +9.4 |
| 2023 | +27.7 | -29.7 | -7.3 | +99.4 | -8.9 | +46.0 | +54.3 | -22.0 | -24.0 | -22.8 | -13.7 | +249.6 |
| 2024 | +19.6 | -4.6 | -26.2 | -13.2 | -40.6 | -11.9 | +18.9 | -2.0 | -2.1 | +47.0 | -26.6 | -15.0 |
| 2025 | -4.7 | -12.6 | -5.2 | +35.0 | +1.5 | +26.8 | +2.8 | +19.2 | +21.4 | +1.3 | +19.1 | +28.1 |
| 2026 | -22.7 | +32.1 | -29.7 | +1.4 | +1.8 | +8.7 | -7.2 | -63.8 | -28.6 | -89.2 | -2.7 |



